• Juni 5, 2021


All affinity constants or in the order of 5.108 M-1 to 7.109 M-1

Some of the indicated ratios are based on a limited number of experiments and are therefore only indicative.

(2)       ND: Not determined.

(3)       See also Debrock S et al. Biochim Biophys Acta 1337, 257-266, 1997.

(4)       S: induction of substrate form

L: accelerated conversion to the latent form

NR: Generation of a non-reactive form (not further investigated whether this non-reactive form is the latent form or is reactive-site blocked by the antibody)

(5)       See also Verhamme I et al. J Biol Chem 274, 17511-17517, 1999.

(6)       ‘thIs5A’: residues R300, Q303, and D305; + contribution from hC and hI; see also Naessens D et al. J.Thromb.Hemostasis. 1, 1028-1033, 2003

‘hF’: residues E128-R131 and K154; see also Bijnens AP et al. J.Biol. Chem 275, 6375-6380, 2000

‘ts3BhG and RCL’; see also Bijnens et al. J Biol Chem 276, 44912-44918, 2001

‘E212/E220’; see also Ngo TH et al. J Biol Chem 276, 26243-26248, 2001

 ‘K88/D89/K176/H229’; see also Naessens et al. Thromb Haemost 90, 52-58,  2003.

(7)       Cross-reactivity evaluated on ELISA using coated recombinant antigen (human (hu), monkey C. aethiops (Cae), rat (rat), murine (mu), rabbit (rab), porcine (PO)).

In some cases, it has been observed that a negative outcome in this essay does not a priori exclude binding in the soluble phase (as evidenced in an assay evaluating the inhibition of PAI-1 activity in solution)

(8)       Concomitant to neutralization of PAI-1 activity, this antibody induces an increased vitronectin binding of PAI-1, also resulting in a decreased cell migration. See also Ngo TH et al. J Biol Chem 276, 26243-26248, 2001


(a)     Berry CN et al. Br J Pharmacology 125, 29-34, 1998.

(b)     Rupin A et al. Abstract 1021 at ISTH Congress in Washington DC (August 1999), Thromb Hemostasis 82 (1999). Rupin A et al Thromb Haemost 86,1528-1531,2001

(c)     Ngo TH et al. Fibrinolysis & Proteolysis 12, 335-339, 1998.

(d)     Montes R et al. Thromb Haemost 84, 65-70, 2000.

(e)     Schoots IG et al. Thromb Haemost 91, 497-505, 2004.


Isotype of MA-8H9D4        IgG1(kappa)

Isotype of MA-33H1F7       IgG1(kappa)

Isotype of MA-55F4C12     IgG1(kappa)

Isotype of MA-33B8           IgG1(kappa)

Isotype of MA-35A5           IgG1(kappa)

Isotype of MA-56A7C10    IgG1(kappa)

Isotype of MA-124K1          IgG1(kappa)

Isotype of MA-31C9            IgG1(kappa)         Control non-inhibitory antibody, reacts only with human PAI-1, not with murine, rat nor rabbit, very low (if any) with porcine

Isotype of MA-32K3            IgG1(kappa)         Control non-inhibitory antibody, reacts only with rat PAI-1, not with human, porcine, murine nor rabbit

Isotype of MA-14D5           IgG1(kappa)         Antibody detecting a neo-epitope in complexed PAI-1

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert